The second part of this study dealt with the evaluation of module-prepared [18F]DCFPyL in preclinical prostate cancer models to further confirm pharmaceutical quality and suitability of the radiotracer for PET imaging of PSMA in vivo. This evidence concerns the gene FOLH1 and prostate cancer.